


Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/817,312		
		Filing Date	April 1, 2004		
		First Named Inventor	Stephen S. Palmer		
		Art Unit	1653		
		Examiner Name	Desai, Anand U.		
Sheet 1	1	of	1	Attorney Docket Number	05558.0011.NPUS04

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C32	Sher, G., et al., "Vaginal Sildenafil (Viagra): A Preliminary Report of a Novel Method to Improve Uterine Artery Blood Flow and Endometrial Development in Patients Undergoing IVF," Human Reproduction, Vol. 15, No. 4, pp. 806 - 809 (2000)	

Examiner Signature		Date Considered	2/26/06
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Not considered
see Interview Summary of 2/26/2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Stephen S. Palmer, et al.
App. No.:	10/817,312
Conf. No.:	1876
Filing Date:	April 1, 2004
Title:	INHIBITORS OF PHOSPHODIESTERASES IN INFERTILITY
Art Unit:	1653
Examiner:	Anand U. Desai, Ph.D.

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 and 1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

DO
Not
ENTER

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB/08B. It is respectfully requested that this Information Disclosure Statement be entered and the document listed on attached Form PTO/SB/08B be considered by the Examiner and made of record.

Not
considered
fails to
comply
w/ 37 CFR
1.97(e).

In accordance with 37 C.F.R. § 1.97(g), this Information Disclosure Statement is not to be construed as a representation that a search has been made. In accordance with 37 C.F.R. § 1.97(h), this Information Disclosure Statement is not to be construed as an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

APD
2/26/06

Application No. 10/817,312
Filed: April 1, 2004
Page 2

Docket No. 055558.0011.NPUS04

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any additional fees under 37 C.F.R. §§1.16 to 1.21 be deemed necessary for any reasons relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey Simon Arnold & White, LLP Deposit Account 08-3038 referencing the above-identified attorney docket number.

Respectfully submitted,

HOWREY LLP

Dated: January 19, 2006

By: / Teddy C. Scott, Jr., Ph.D. /
Teddy C. Scott, Jr., Ph.D.
Registration No.: 53,573
Customer No.: 22930

HOWREY LLP
321 N. Clark Street, Suite 3400
Chicago, IL 60661
(312) 595-1239 (main)
(312) 846-5621 (direct)
(312) 595-2250 (fax)